EICHORCondition: Solid Tumor · Sponsor: Abbisko Therapeutics Co, Ltd
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK061 administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK061 at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.
This description comes directly from the study's public registry record.
Yuan LU · +86 21 68910052 · clinical@abbisko.com
Always discuss trial participation with your own doctor first.
| Mary Crowley Cancer Research | Dallas, Texas, United States | Recruiting |
| Yuan LU | Shanghai, Abbisko Therapeutics Co., Ltd. 12B Floor, Building 1, Lane 515, China | Recruiting |
| The First Affiliated Hospital of Bengbu Medical College | Bengbu, Anhui, China | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Chongqing Daping Hospital | Chongqing, Chongqing Municipality, China | Not Yet Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, Gongshu District, China | Recruiting |
| Sun Yat-sen Memorial Hospital/ the Second Affiliated Hospital of Sun Yat-sen University | Guanzhou, Guangdong, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Not Yet Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05244551